FDA Approves Eli Lilly’s Foundayo Oral GLP‑1 Obesity Drug With Flexible Anytime Dosing
The FDA has approved Eli Lilly’s oral GLP‑1 obesity pill Foundayo (generic orforglipron), which—unlike oral Wegovy—can be taken anytime without food or drink restrictions; the agency completed review in 50 days under a new expedited program and the drug will be included in a federal deal to lower GLP‑1 prices. Clinical trials showed a mean weight loss of about 11.2% (~25 pounds) at the 36 mg dose versus 2.1% for placebo with higher GI‑side‑effect discontinuation (≈5–10% vs ≈3%), regulators flagged thyroid‑tumor/cancer warnings, pricing is expected at $149–$349/month (insured patients possibly $25/month with a Lilly card), and Eli Lilly’s shares rose after the approval.
📌 Key Facts
- The FDA approved Eli Lilly’s oral GLP‑1 weight‑loss pill Foundayo (generic name orforglipron).
- Foundayo can be taken at any time of day without fasting or timing restrictions, unlike competing oral Wegovy which must be taken on an empty stomach with a 30‑minute wait before eating or drinking.
- The FDA completed its review of Foundayo in 50 days under a new expedited-approval program aimed at cutting drug approval times.
- Clinical trial results reported mean weight loss of roughly 11–12% (about 25–27 pounds) at the highest doses over ~16+ months; discontinuation for gastrointestinal side effects occurred in about 5–10% of patients on orforglipron versus ~3% on placebo.
- Regulatory and labeling safety information includes a Lilly warning about thyroid tumors/thyroid cancer risk and an expanded side‑effect profile that lists extensive gastrointestinal symptoms and reports of hair loss.
- U.S. list pricing was reported in the range of $149–$349 per month depending on dose, with insured patients potentially paying about $25/month using a Lilly discount card; Foundayo will be included in a Trump administration deal to lower GLP‑1 prices.
- Market and usage context: more than 600,000 prescriptions have already been written for Novo Nordisk’s competing oral Wegovy since its December approval, and about 1 in 8 people in the U.S. have used injectable GLP‑1 drugs (KFF survey); Eli Lilly’s stock rose more than 4% in afternoon trading after the approval.
- Eli Lilly is studying Foundayo for additional indications including type 2 diabetes, obstructive sleep apnea, knee osteoarthritis pain, hypertension, peripheral artery disease and stress urinary incontinence.
- Coverage included on‑the‑record comments from experts and industry — including Deborah Horn (UTHealth Houston) and Lilly CEO David Ricks — about access barriers, stigma and how an oral GLP‑1 could “level the playing field” for obesity treatment.
📊 Relevant Data
In 2022, the age-standardized prevalence of obesity among non-Hispanic Black females in the US was 56.9%, compared to 49.4% among Hispanic females and 40.1% among non-Hispanic White females.
In 2022, the age-standardized prevalence of obesity among Hispanic males in the US was 45.7%, compared to 42.5% among non-Hispanic Black males and 40.1% among non-Hispanic White males; overall adult obesity prevalence was 42.5%, with projections to increase to around 46.9% by 2035.
Prevalence of Obesity in US Set to Reach 46.9% by 2035 — empr.com
US population demographics in 2023 show non-Hispanic Whites at approximately 59%, Hispanics at 19%, and non-Hispanic Blacks at 13%, providing context for per capita obesity disparities where Black females have an obesity rate of 56.9% despite comprising a smaller population share.
📰 Source Timeline (4)
Follow how coverage of this story developed over time
- Fox article emphasizes that Foundayo is currently the only GLP‑1 weight‑loss pill that can be taken at any time of day without food or water restrictions, contrasting it with oral Wegovy.
- Cites Eli Lilly press‑release data that patients on the highest Foundayo dose lost an average of 27.3 pounds, or 12.4% of body weight, in clinical trials.
- Details a broader development program: Foundayo is being studied for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.
- Includes new on‑the‑record quotes from Deborah Horn (UTHealth Houston) and Lilly CEO David Ricks about access barriers, stigma and how an oral GLP‑1 could “level the playing field” for obesity treatment.
- Spells out Lilly’s thyroid‑tumor and thyroid‑cancer warning and lists an expanded side‑effect profile, including hair loss and extensive gastrointestinal symptoms.
- This CBS item confirms in general terms that the FDA has approved a new Eli Lilly GLP‑1 weight‑loss drug but provides no additional specifics beyond what the earlier detailed story already carried.
- The segment is framed as an explainer by Dr. Jon LaPook rather than adding new trial data, pricing figures, or regulatory nuances.
- No new quotes from FDA officials or Eli Lilly executives are included in the text provided.
- Confirms the generic name orforglipron and reiterates the brand name Foundayo as a GLP‑1 pill mimicking natural appetite hormones.
- Specifies that FDA completed its review in 50 days under a new expedited-approval program aimed at cutting drug approval times.
- Provides concrete U.S. cash pricing ranges: $149–$349 per month depending on dose, with insured patients potentially paying $25/month via a Lilly discount card.
- States that more than 600,000 prescriptions have already been written for Novo Nordisk’s competing oral Wegovy pill since its December approval.
- Details that about 1 in 8 people in the U.S. have used injectable GLP‑1 drugs, citing a KFF survey.
- Clarifies that Foundayo will be included in a Trump administration deal to lower prices on GLP‑1 drugs.
- Reports that Eli Lilly’s stock rose more than 4% in Wednesday afternoon trading after the approval.
- Adds exact trial outcome wording from NEJM: 11.2% mean weight loss (~25 pounds) at 36 mg over more than 16 months vs 2.1% (~<5 pounds) on placebo, and that 5–10% of patients on orforglipron discontinued due to GI side effects vs nearly 3% on placebo.
- Reiterates usage distinction: orforglipron can be taken without fasting or timing restrictions, while the Wegovy pill must be taken on an empty stomach with a 30‑minute wait before eating or drinking.